Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi)
- C. Tarella
- M. Zanni
- M. Di Nicola
- C. Patti
- R. Calvi
- A. Pescarollo
- V. Zoli
- A. Fornari
- D. Novero
- A. Cabras
- M. Stella
- A. Comino
- D. Remotti
- M. Ponzoni
- D. Caracciolo
- M. Ladetto
- M. Magni
- L. Devizzi
- R. Rosato
- M. Boccadoro
- M. Bregni
- A. Gallamini
- I. Majolino
- S. Mirto
- Gruppo italiano terapie innovative nei linfomi
- P. Corradini
- A.M. Gianni
DOIAbstract
A prospective multicenter program was performed to evaluate the combination of rituximab and high-dose (hd) sequential chemotherapy delivered with multiple autologous peripheral blood progenitor cell (PBPC) support (R-HDS-maps regimen) in previously untreated patients with diffuse large B-cell lymphoma (DLB-CL) and age-adjusted International Prognostic Score (aaIPI) score 2-3. R-HDS-maps includes: (i) three APO courses; (ii) sequential administration of hd-cyclophosphamide (CY), hd-Ara-C, both supplemented with rituximab, hd-etoposide/cisplatin, PBPC harvests, following hd-CY and hd-Ara-C; (iii) hd-mitoxantrone (hd-Mito)/L-Pam + 2 further rituximab doses; (iv) involved-field radiotherapy. PBPC rescue was scheduled following Ara-C, etoposide...
Add to ORKG